| Titre |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma |
| Protocole ID |
GOLSEEK-1 |
| ClinicalTrials.gov ID |
NCT06356129 |
| Type(s) de cancer |
Lymphome non-hodgkinien (LNH) |
| Phase |
Phase III |
| Stade |
Lymphome diffus à grandes cellules B |
| Type étude |
Clinique |
| Médicament |
Golcadomide + R-CHOP Chemotherapy versus placebo + R-CHOP |
| Institution |
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
 HOPITAL FLEURIMONT
3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
|
| Ville |
Sherbrooke |
| Investigateur(trice) principal(e) |
Dre Stéphanie Corriveau-Désilets
|
| Coordonnateur(trice) |
Anick Champoux
819-346-1110 poste 12811
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including:
- Diffuse large B-cell lymphoma (DLBCL), not otherwise specified [including germinal center B-cell (GCB) and activated B-cell (ABC) types]
- High-grade B-cell lymphoma, with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma, not otherwise specified
- iT-cell/histiocyte/rich large B-cell lymphoma (THRLBCL)
- Epstein-Barr virus + DLBCL
- International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) ≥ 1.3 x upper limit of normal (ULN) and/or bulky disease defined as single lesion of ≥ 7 cm OR IPI ≥ 3.
- Measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification.
- Must have Ann Arbor Stage II-IV disease.
|
| Critètes d'exclusion |
- Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
- Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, FL transformed to a-BCL, Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma.
- Documented or suspected central nervous system (CNS) involvement by lymphoma.
- Other protocol-defined Inclusion/Exclusion criteria apply.
|
Groupe d'étude en oncologie du Québec